Chartwell Investment Partners LLC increased its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)


Chartwell Investment Partners LLC boosted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating ) by 4.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,047 shares of the medical device company’s stock after buying an additional 713 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Tandem Diabetes Care were worth $1,982,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of TNDM. Moors & Cabot Inc. purchased a new stake in Tandem Diabetes Care in the third quarter valued at $25,000. Exane Derivatives purchased a new stake in Tandem Diabetes Care in the first quarter valued at $33,000. Byrne Asset Management LLC purchased a new stake in shares of Tandem Diabetes Care in the 4th th quarter, valued at $34,000. Retirement Planning Co of New England Inc. purchased a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at $48,000. Finally, KRS Capital Management LLC purchased a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at $60,000. Institutional Investors Own 94.62% of the company’s shares.

TNDM has been the subject of several analyst reports. Piper Sandler reduced their target price on Tandem Diabetes Care from $170.00 to $120.00 in a report on Thursday, May 5th. StockNews.com downgraded Tandem Diabetes Care from a “hold” rating to a “sell” rating in a report on Friday, July 1st. Citigroup cut their target price on Tandem Diabetes Care from $155.00 to $130.00 in a report on Tuesday, May 17th. Oppenheimer reduced their price objective on Tandem Diabetes Care from $142.00 to $130.00 in a report on Thursday, May 5th. Finally, TheStreet lowered Tandem Diabetes Care from a “c-” rating to a “d+” rating in a research note on Monday, June 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Moderate Buy” and an average target price of $143.00, according to MarketBeat.com.

NASDAQ:TNDM opened at $60.70 on Monday. The stock has a 50-day simple moving average of $66.63 and a 200-day simple moving average of $100.35. The stock has a market cap of $3.88 billion, a P/E ratio of 758.84 and a beta of 0.77. Tandem Diabetes Care, Inc. has a 1-year low of $52.69 and a 1-year high of $155.86. The company has a debt-to-equity ratio of 0.64, a quick earnings ratio of 5.60 and a current ratio of 6.21.

Tandem Diabetes Care (NASDAQ:TNDM – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The medical devices company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $175.91 million for the quarter, compared to analyst estimates of $168.21 million. Tandem Diabetes Care had a return on equity of 1.64% and a net margin of 0.80%. The company’s revenue was up 24.7% over the same quarter last year. During the same period last year, the company reported ($0.07) earnings per share. On average, equities analysts predict that Tandem Diabetes Care, Inc. will post 0.35 EPS for the current year.

In related news, director Christopher J. Toomey sold 248 shares of the company’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $111.73, for a total value of $27,709.04. Following the completion of the sale, the director now directly owns 5,112 shares of the company’s stock, valued at approximately $571,163.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC’s website. Also, Director Rebecca B. Robertson sold 1,500 shares of the company’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $96.73, for a total value of $145,095.00. Disclosure of this sale can be found here. Over the last ninety days, insiders bought 5,000 shares of company stock valued at $361,270 and sold 22,607 shares valued at $1,829,208. Corporate insiders own 2.20% of the company’s shares.

Profile of Tandem Diabetes Care (Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops and markets a variety of products for people with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform that consists of the t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured stories

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating ).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)



Get Tandem Diabetes Care news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tandem Diabetes Care and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.